The DOI matches its Crossref record.
Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project
Open accessAbstract
BACKGROUND: In the INRG dataset, the hypothesis that any segmental chromosomal alteration might be of prognostic impact in neuroblastoma without MYCN amplification (MNA) was tested. METHODS: The presence of any segmental chromosomal alteration (chromosome 1p deletion, 11q deletion and/or chromosome 17q gain) defined a segmental genomic profile. Only tumours with a confirmed unaltered status for all three chromosome arms were considered as having no segmental chromosomal alterations. RESULTS: Among the 8800 patients in the INRG database, a genomic type could be attributed for 505 patients without MNA: 397 cases had a segmental genomic type, whereas 108 cases had an absence of any segmental alteration. A segmental genomic type was more frequent in patients >18 months and in stage 4 disease (P<0.0001). In univariate analysis, 11q deletion, 17q gain and a segmental genomic type were associated with a poorer event-free survival (EFS) (P<0.0001, P=0.0002 and P<0.0001, respectively). In multivariate analysis modelling EFS, the parameters age, stage and a segmental genomic type were retained in the model, whereas the individual genetic markers were not (P<0.0001 and RR=2.56; P=0.0002 and RR=1.8; P=0.01 and RR=1.7, respectively). CONCLUSION: A segmental genomic profile, rather than the single genetic markers, adds prognostic information to the clinical markers age and stage in neuroblastoma patients without MNA, underlining the importance of pangenomic studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group
Irwin, M. S., Naranjo, A., Zhang, F. F., Cohn, S. L., London, W. B., Gastier-Foster, J. M., Ramirez, N. C., Pfau, R., Reshmi, S., Wagner, E., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00278 · Cited by 494
Self-citationOverview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas
Mete, O., Asa, S. L., Gill, A. J., Kimura, N., de Krijger, R. R., & Tischler, A. (2022) · Endocrine Pathology · doi:10.1007/s12022-022-09704-6 · Cited by 424
Irwin, M. S., & Park, J. R. (2015) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2014.09.015 · Cited by 392
Neuroblastoma: Molecular Pathogenesis and Therapy
Louis, C. U., & Shohet, J. M. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-011514-023121 · Cited by 354
Neuroblastoma: clinical and biological approach to risk stratification and treatment
Tolbert, V. P., & Matthay, K. K. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2821-2 · Cited by 304
Self-citationMechanisms of neuroblastoma regression
Brodeur, G. M., & Bagatell, R. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.168 · Cited by 284
Self-citationKrajewska, M., Dries, R., Grassetti, A. V., Dust, S., Gao, Y., Huang, H., Sharma, B., Day, D. S., Kwiatkowski, N., Pomaville, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09703-y · Cited by 281
Updates in Diagnosis, Management, and Treatment of Neuroblastoma
Swift, C. C., Eklund, M. J., Kraveka, J. M., & Alazraki, A. L. (2018) · RadioGraphics · doi:10.1148/rg.2018170132 · Cited by 279
Metadata
- Authors
- Schleiermacher, G., Mosseri, V, London, W. B., Maris, J. M., Brodeur, G. M., Attiyeh, E., Haber, M., Khan, J., Nakagawara, A., Speleman, F., Noguera, R., Tonini, G. P., Fischer, M., Ambros, I., Monclair, T., Matthay, K. K., Ambros, P., Cohn, S. L., & Pearson, A. D. J.
- Venue
- British Journal of Cancer
- Published
- 2012-09-13
- Volume
- 107
- Issue
- 8
- Pages
- 1418-1422
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2150823346
- Cited by
- 192
- References
- 0
- FWCI
- 5.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.